Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.38 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656203 | 0.85 | GRIN1 (0.71) | GRIN1GRIN2BKMT2AMEN1MAPT | |
| SCHEMBL13656210 | 0.85 | KMT2A (0.56) | GRIN1GRIN2BKCNH2KMT2AMEN1 | |
| SCHEMBL13656204 | 0.85 | GRIN1 (0.64) | GRIN1GRIN2BKCNH2KMT2APYGL | |
| SCHEMBL13656223 | 0.85 | PYGL (0.60) | GRIN1GRIN2BKCNH2KMT2APYGL | |
| SCHEMBL12575959 | 0.84 | GRIN1 (0.53) | GRIN1GRIN2BKCNH2KMT2AMEN1 | |
| SCHEMBL2020401 | 0.81 | GRIN1 (0.70) | GRIN1GRIN2BKCNH2KMT2AMEN1 | |
| SCHEMBL13656209 | 0.78 | GRIN1 (0.67) | GRIN1GRIN2BKCNH2KMT2APYGL | |
| SCHEMBL13656110 | 0.74 | GRIN1 (0.67) | GRIN1GRIN2BKMT2AMEN1RAB9A | |
| SCHEMBL13656207 | 0.73 | GRIN1 (0.69) | GRIN1GRIN2BPYGLSMN1; SMN2 | |
| SCHEMBL13656132 | 0.71 | GRIN1 (0.67) | GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885KCNH2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.